10 May 2007 -
CytoGenix, Inc. (OTCBB:CYGX) announced today that it has executed a Letter of Intent regarding synDNA[TM] development with Eurogentec S.A.
The Companies have identified an area of mutual interest regarding development of synDNA[TM] and will collaborate to optimize manufacturing and to implement purification and quality control parameters. A successful collaboration will facilitate submission of European Union (EU) regulatory filings with products containing synDNA[TM].
Malcolm Skolnick, CytoGenix President/CEO, stated, "Eurogentec is an excellent process development partner for synDNA[TM]. The collaboration will allow us to accelerate the entry of synDNA[TM] as a drug substance for clients within the EU. Eurogentec brings a wealth of process development and EU regulatory filing experience to the collaboration."
Dr. Phillippe Cronet, Director of Eurogentec's Biologics Business Unit, commented, "CytoGenix synDNA[TM] has the potential to make a significant impact as a source of drug substance for a wide array of DNA-based medicine. We are looking forward to establishing a collaborative relationship with CytoGenix."
CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary synDNA(TM) production and ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of high purity DNA that can be made faster and cleaner than production using traditional fermentation methods and has developed a novel expression vector that enables production of ssDNA sequences inside the cell. CytoGenix currently holds 11 granted patents and about 36 international or US pending patent applications claiming methods and materials in connection with these platform technologies.
Regarding Eurogentec
Eurogentec was founded in 1985 as a spin-off of the University of Li[c]ge (Belgium). Its mission is to design and deliver reliable and innovative services and products for the Life-Science community. As a leading supplier for genomic and proteomic research, Eurogentec is able to offer its customers integrated solutions, whether they use DNA, antibodies, peptides or proteins as research tools. Eurogentec also offers research and development services for the biopharmaceutical industry.
Back to news list
|
|